Back to search results
NCT04753320

Remote Monitoring in Progressive Supranuclear Palsy (PSP)

Not Yet Recruiting
Not specifiedAges 18–89Observational
Massachusetts General Hospital
~85 participants
Updated 2026-07-29 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary feasibility outcome
Measured over 12 months

Conditions

Progressive Supranuclear Palsy
Parkinson Disease
MSA - Multiple System Atrophy

Explore related trials

Multiple System AtrophyParkinson DiseaseProgressive Supranuclear Palsy

NCT04753320

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Johns Hopkins

    Baltimore, Marylandstudy coordinator listed

  • Massachusetts General Hospital

    Boston, Massachusettsstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Anne-Marie A Wills, MD MPH · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Yvonne Kim, BS
[email protected]
617-643-2400
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of possible or probable PSP phenotype as defined by the 2017 MDS criteria, clinical diagnosis of at least probable PD as defined by the 2015 MDS criteria, or clinical diagnosis of at least probable MSA as defined by the 2022 MDS criteria, or healthy controls.
Male or female, aged 18 to 89 years, inclusive.
Fluent in reading and speaking English.
Capable of providing informed consent based on the investigator's judgment.
Able to comply with the protocol based on the investigator's judgment.
Able to walk 10 feet unassisted.
With access to a caregiver who is able to assist with all study-related procedures.

Exclusion

Any neurological, medical, or psychiatric condition that would preclude participation in study activities based on the investigator's judgment.
A history of frequent falls defined as more than 5 falls/month or requirement of a walker to ambulate safely.

What this trial measures

  • Primary feasibility outcome12 months

    Compliance will be calculated as the number of participants who wear their PAMSys pendant sensors at least 16 hours/day for at least 180 days and complete at least 80% of their scheduled monthly sensor and tablet derived motor, speech, and cognitive assessments through their 6 month visit.